Lakefront Biotherapeutics NV (GLPGN) Stock Statistics & Valuation Metrics
Total Valuation
Lakefront Biotherapeutics NV has a market cap or net worth of $40.12B. The enterprise value is -$394.90M.
- Market Cap
- $40.12B
- Enterprise Value
- -$394.90M
Share Statistics
Lakefront Biotherapeutics NV has 65,897,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 65,897,070
- Owned by Insiders
- ―
- Owned by Institutions
- 7.83%
Financial Efficiency
Lakefront Biotherapeutics NV’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 14.43%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 14.43%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 2.46M
- Profits Per Employee
- 709.92K
- Employee Count
- 452
- Asset Turnover
- 0.33
- Inventory Turnover
- 3.63
Valuation Ratios
The current PE Ratio of Lakefront Biotherapeutics NV is 3.91. Lakefront Biotherapeutics NV’s PEG ratio is -0.10.
- PE Ratio
- 3.91
- PS Ratio
- 1.82
- PB Ratio
- 0.59
- Price to FCF
- -6.31
- Price to Operating Cash Flow
- -6.52
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Lakefront Biotherapeutics NV had revenue of 1.11B and earned 320.88M in profits. Earnings per share was 4.87.
- Revenue
- 1.11B
- Gross Profit
- 1.03B
- Operating Income
- 469.66M
- Pretax Income
- 300.87M
- Net Income
- 320.88M
- EBITDA
- 521.51M
- Earnings Per Share (EPS)
- 4.87
Cash Flow
In the last 12 months, operating cash flow was -292.39M and capital expenditures -8.73M, giving a free cash flow of -301.12M billion.
- Operating Cash Flow
- -292.39M
- Free Cash Flow
- -301.12M
- Free Cash Flow per Share
- -4.57
Dividends & Yields
Lakefront Biotherapeutics NV pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.86%
- Earnings Yield
- 25.65%
Important Dates
Lakefront Biotherapeutics NV upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Lakefront Biotherapeutics NV as a current ratio of 20.15, with Debt / Equity ratio of 0.21%
- Current Ratio
- 20.15
- Quick Ratio
- 20.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.16
- Interest Coverage Ratio
- 279.56
Taxes
In the past 12 months, Lakefront Biotherapeutics NV has paid -18.62M in taxes.
- Income Tax
- -18.62M
- Effective Tax Rate
- -0.06
Enterprise Valuation
Lakefront Biotherapeutics NV EV to EBITDA ratio is 5.30, with an EV/FCF ratio of -6.11.
- EV to Sales
- 1.76
- EV to EBITDA
- 5.30
- EV to Free Cash Flow
- -6.11
- EV to Operating Cash Flow
- -6.29
Balance Sheet
Lakefront Biotherapeutics NV has $2.98B in cash and marketable securities with $6.43M in debt, giving a net cash position of $2.98B billion.
- Cash & Marketable Securities
- $2.98B
- Total Debt
- $6.43M
- Net Cash
- $2.98B
- Net Cash Per Share
- $45.16
- Tangible Book Value Per Share
- $49.36
Margins
Gross margin is 98.01%, with operating margin of 36.43%, and net profit margin of 46.83%.
- Gross Margin
- 98.01%
- Operating Margin
- 36.43%
- Pretax Margin
- 45.14%
- Net Profit Margin
- 46.83%
- EBITDA Margin
- 33.26%
- EBIT Margin
- 30.70%
Analyst Forecast
The average price target for Lakefront Biotherapeutics NV is $525.24, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
- Price Target
- $525.24
- Price Target Upside
- ―
- Analyst Consensus
- Moderate Sell
- Analyst Count
- 2
- Revenue Growth Forecast
- 256.82%
- EPS Growth Forecast
- ―